Clinical and Vaccine Immunology · 2013 · 38 citations · 22 references
Life SciencesImmunologyMicrobiologyAdaptive ImmunityImmunology Of Infectious DiseasesMucosal ImmunologyAntibody-antigen RecognitionGastrointestinal ImmunologyHumoral ImmunityMucosal Immune SystemMucosal ImmunityMucosal ImmunizationBacterial Lipopolysaccharide RecognitionEnzyme-linked Immunosorbent Assay (Elisa)Gut Homing Of LymphocytesImmunologic MemoryOral VaccinationPlasmablast ResponsesVaccine-induced Antibody ResponsesVibrio Infections
Infection with Vibrio cholerae and oral cholera vaccines (OCVs) induce transient circulating plasmablast responses that peak within approximately 7 days after infection or vaccination. We previously demonstrated that plasmablast responses strongly correlate with subsequent levels of V. cholerae-specific duodenal antibodies up to 6 months after V. cholerae infection. Hence, plasmablast responses provide an early window into the immunologic memory at the mucosal surface. In this study, we characterized plasmablast responses following V. cholerae infection using a flow cytometrically defined population and compared V. cholerae-specific responses in adult patients with V. cholerae O1 infection and vaccinees who received the OCV Dukoral (Crucell Vaccines Canada). Among flow cytometrically sorted populations of gut-homing plasmablasts, almost 50% of the cells recognized either cholera toxin B subunit (CtxB) or V. cholerae O1 lipopolysaccharide (LPS). Using a traditional enzyme-linked immunosorbent spot assay (ELISPOT), we found that infection with V. cholerae O1 and OCVs induce similar responses to the protein antigen CtxB, but responses to LPS were diminished after OCV compared to those after natural V. cholerae infection. A second dose of OCV on day 14 failed to boost circulating V. cholerae-specific plasmablast responses in Bangladeshi adults. Our results differ from those in studies from areas where cholera is not endemic, in which a second vaccination on day 14 significantly boosts plasmablast responses. Given these results, it is likely that the optimal boosting strategies for OCVs differ significantly between areas where V. cholerae infection is endemic and those where it is not.
22
Rapid cloning of high-affinity human monoclonal antibodies against influenza virus
Jens Wrammert, Kenneth G. C. Smith, Joe Miller et al. · Nature · 2008 · 1.1K citations · Full text
Jens Wrammert, Dimitrios Koutsonanos, Guimei Li et al. · The Journal of Experimental Medicine · 2011 · 802 citations · Full text
Refractory periods and climate forcing in cholera dynamics
Katia Koelle, Xavier Rodó, Mercedes Pascual et al. · Nature · 2005 · 426 citations · Full text
ENDEMIC CHOLERA IN RURAL BANGLADESH, 1966–1980
Roger I. Glass, Stan Becker, M. I. Huq et al. · American Journal of Epidemiology · 1982 · 361 citations